Biosynthetic gene cluster of aromatic polyketone antibiotic alboFungins as well as preparation method and application of biosynthetic gene cluster

Through cloning and heterologous expression of albofungins biosynthetic gene clusters, the xanthone antibiotics were successfully prepared, solving their application problems in antibacterial, anti-tumor and hypoglycemic drugs, demonstrating strong antibacterial activity and tumor suppression effects, and Promote GLP-1 secretion and realize new methods for diversified synthesis and drug development.

CN118910100APending Publication Date: 2024-11-08YANTAI NEW DRUG DEV SHANDONG PROVINCIAL LAB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410972013.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prepare and apply the albofungins, anthracene aromatic polyketone antibiotic, which limits its application in antibacterial, antitumor and hypoglycemic drugs.

Method used

By cloning and heterologously expressing albofungins biosynthetic gene clusters, gene assembly was performed using FnCas12a precise targeted cleavage and Cre-loxP system to achieve heterologous expression in Streptocytica S.albus J1074, and then obtained by fermentation extraction and isolation purification albofungins, chrestoxanthones A and chrestoxanthones C.

Benefits of technology

Achieving the diverse synthesis of albofungins, providing new methods for antibacterial, antitumor and promoting GLP-1 secretion drugs, demonstrating powerful antibacterial activity against a variety of bacteria and fungi, and showing in tumor cells and colorectal cancer cells It significantly inhibits activity, promotes the secretion of GLP-1 and reduces blood sugar.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910100A_ABST
    Figure CN118910100A_ABST
Patent Text Reader

Abstract

The invention provides a biosynthetic gene cluster of aromatic polyketone antibiotics albofungins, a preparation method and an application of the biosynthetic gene cluster. According to the present invention, the source of the biosynthesis gene cluster of the alboFungins is Streptomyces mononomycin NRRL B-24309, and the nucleotide sequence of the biosynthesis gene cluster of the aromatic polyketone antibiotic alboFungins is the 9893 base group to the 69075 base group of the nucleotide sequence of the NCBI Reference Sequence: NZKL571059.1. The gene cluster direct cloning and heterologous expression combined method provided by the invention can provide an effective strategy for discovery of novel natural products. The separated compounds shown in the formula 1, the formula 2 and the formula 3 show extremely high antibacterial activity on various bacteria and fungi, and the compounds are expected to be developed into new antibacterial drugs after being subjected to biological engineering modification or chemical modification. In addition, the invention provides application of the compounds as shown in the formula 1, the formula 2 and the formula 3 in preparation of antitumor drugs, drugs for promoting GLP-1 secretion and hypoglycemic drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The patent of this invention relates to the field of microbial technology, and in particular to an in vitro cloning and expression of a biosynthetic gene cluster of aromatic polyketide antibiotics albofungins, a preparation method, and its application in the preparation of antibacterial, anti-tumor, and GLP-1 secretion-promoting drugs. Background Art

[0002] Albofungins are a class of xanthone aromatic polyketides with a highly oxidized 6 / 6 / 6 / 6 / 6 / 6 hexacyclic core skeleton structure, and some compounds contain unique aminoamide structures. This class of compounds exhibits broad-spectrum resistance to bacteria, fungi and tumor cells, and has great application prospects in drug development. Summary of the invention

[0003] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. Therefore, in a first aspect of the present invention, the present invention provides an aromatic polyketide antibiotic albofungins biosynthetic gene cluster, the nucleotide sequence of the aromatic polyketide antibiotic albofungins biosynthetic gene cluster is the 9893-69075 bases of the nucleotide sequence of NCBI Reference Sequence: NZ_KL571059.1.

[0004] In one or more embodiments of the present invention, the biosynthetic gene cluster of the aromatic polyketide antibiotic albofungins comprises 61 coding genes and 59183 bases. The coding genes are shown in Table 1, and the coding genes include genes encoding type II polyketide synthase, chain length elongation factors, regulatory genes, transport proteins, and multifunctional oxidoreductases.

[0005] In the second aspect of the present invention, the present invention provides the use of the aromatic polyketide antibiotic albofungins biosynthetic gene cluster provided in the first aspect of the present invention in the preparation of compounds represented by Formula 1, Formula 2, and Formula 3, wherein the structural formulas of the compounds represented by Formula 1, Formula 2, and Formula 3 are as follows:

[0006]

[0007] In the third aspect of the present invention, the present invention provides a method for preparing the compounds represented by Formula 1, Formula 2 and Formula 3, comprising the following steps:

[0008] a. cloning and heterologous expression in vitro of the albofungins biosynthetic gene cluster of the aromatic polyketide antibiotics described in the first aspect of the present invention;

[0009] b. fermenting the heterologously expressed recombinant strain in step a, separating the mycelium and the fermentation broth, extracting the mycelium to obtain extract A, and extracting the fermentation broth to obtain extract B;

[0010] c. Mix the extract A and the extract B to obtain a total extract, separate and purify the total extract to obtain the compounds represented by Formula 1, Formula 2, and Formula 3.

[0011] The structural formulas of the compounds represented by Formula 1, Formula 2 and Formula 3 are as follows:

[0012]

[0013] In one or more embodiments of the present invention, in step a, the heterologous expression of the biosynthetic gene cluster is carried out in Streptomyces albus J1074.

[0014] Specifically, step a comprises: 1) using FnCas12a to precisely target and cut the S. monomycini NRRL B-24309 genome to obtain the aromatic polyketide antibiotic albofungins biosynthetic gene cluster described in the first aspect of the present invention, 2) T4 DNA polymerase and ligase to perform in vitro linear assembly of the gene cluster and the vector backbone, 3) Cre-loxP system-mediated efficient circularization of linear DNA fragments in vivo, and 4) heterologous expression of the recombinant plasmid in Streptomyces albus S.albus J1074.

[0015] In one or more embodiments of the present invention, in step b, the mycelium is extracted, including: extracting the mycelium with acetone, recovering the acetone from the extract and then extracting with ethyl acetate, and concentrating the ethyl acetate phase under reduced pressure to obtain extract A.

[0016] In one or more embodiments of the present invention, in step b, the fermentation broth is extracted, including: extracting the fermentation broth with ethyl acetate, and concentrating the ethyl acetate phase under reduced pressure to obtain extract B.

[0017] In one or more embodiments of the present invention, in the step c, the total extract is separated and purified, including: mixing the total extract with silica gel, dry-loading the column, gradient elution with n-hexane / ethyl acetate as eluent, detecting with TLC, collecting the same fractions, and obtaining Fr.1-Fr.7 in sequence, and the fraction Fr.6 eluted with ethyl acetate is separated and purified by gel column chromatography (Sephadex-LH20, methanol) and semi-preparative high performance liquid chromatography (semi-HPLC).

[0018] In the fourth aspect of the present invention, the present invention provides an application of a compound represented by Formula 1, Formula 2 or Formula 3 in the preparation of an antibacterial drug, wherein the structural formula of the compound represented by Formula 1, Formula 2 or Formula 3 is as follows:

[0019]

[0020] In one or more embodiments of the present invention, the bacteria include at least one of Bacillus subtilis, Bacillus halodurans, Micrococcus luteus, Streptococcus mutans, Saccharomyces cerevisiae, Streptomyces, Staphylococcus epidermidis, Enterobacter, Pseudomonas fluorescens, Candida and Aspergillus.

[0021] In one or more embodiments of the present invention, the compound represented by Formula 1, Formula 2 or Formula 3 is prepared by the preparation method of the third aspect of the present invention.

[0022] In the fifth aspect of the present invention, the present invention provides a use of a compound represented by Formula 1, Formula 2 or Formula 3 in the preparation of an anti-tumor drug, wherein the structural formula of the compound represented by Formula 1, Formula 2 or Formula 3 is as follows:

[0023]

[0024] The tumor includes at least one of a leukemia tumor and a colorectal cancer tumor.

[0025] In the sixth aspect of the present invention, the present invention provides a use of a compound represented by Formula 1, Formula 2 or Formula 3 in the preparation of a drug for promoting GLP-1 secretion, wherein the structural formula of the compound represented by Formula 1, Formula 2 or Formula 3 is as follows:

[0026]

[0027] Prior art records that promoting GLP-1 secretion helps lower blood sugar.

[0028] That is, the present invention provides an application of a compound represented by Formula 1, Formula 2 or Formula 3 in the preparation of a hypoglycemic drug.

[0029] The beneficial effects of the present invention are:

[0030] 1. The present invention provides a biosynthetic gene cluster of an aromatic polyketide antibiotic albofungins, which is derived from Streptomyces monomycini NRRL B-24309. The biosynthetic gene cluster provides a new method for the diversified synthesis of aromatic polyketide antibiotic albofungins, which can be used to simultaneously prepare compounds represented by Formula 1, Formula 2 and Formula 3;

[0031] 2. The present invention provides a method for simultaneously preparing compounds represented by Formula 1, Formula 2 and Formula 3, providing a new method for the diversified synthesis of aromatic polyketide compounds, and the method of direct cloning combined with heterologous expression can provide an effective strategy for the discovery of new natural products.

[0032] 3. The present invention provides an application of compounds represented by Formula 1, Formula 2 and Formula 3 in the preparation of antibacterial drugs. The compounds represented by Formula 1, Formula 2 and Formula 3 exhibit extremely strong antibacterial activity against a variety of bacteria and fungi. They can be developed into new antibacterial drugs by bioengineering or chemical modification.

[0033] 4. The present invention provides an application of compounds represented by Formula 1, Formula 2 and Formula 3 in the preparation of anti-tumor drugs, drugs for promoting GLP-1 secretion and hypoglycemic drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is a comparison of putative albofungins biosynthetic gene clusters from different bacterial species;

[0035] Figure 2 HPLC analysis of fermentation culture of recombinant strain S.albus J1074::albo;

[0036] Figure 3 It is the agarose gel electrophoresis diagram of E.coli / pBE14 / albo colony PCR;

[0037] Figure 4 The agarose gel electrophoresis diagram of SnaBⅠ digested E.coli / pBE14 / albo plasmid;

[0038] Figure 5 This is the analysis diagram of the anti-tumor activity and GLP-1 secretion promoting activity of compound 1;

[0039] in, Figure 5 A is a graph showing the inhibitory activity of compound 1 (compound albofungin) on leukemia tumor cells; Figure 5 B is a result diagram showing the promotion of GLP-1 secretion activity; Figure 5 C is a result diagram showing the inhibitory activity of compound 1 (compound albofungin) on colorectal cancer cell HCT116; Figure 5 D is a graph showing the inhibitory activity of compound 1 (compound albofungin) on colorectal cancer cells HT29. DETAILED DESCRIPTION

[0040] The present invention will be further described below in conjunction with specific examples and accompanying drawings, but the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. In the following examples, if specific conditions are not specified, they are carried out according to normal conditions or conditions recommended by the manufacturer. The methods used are conventional methods known in the art unless otherwise specified, and the consumables and reagents used are commercially available unless otherwise specified. Unless otherwise specified, the professional and scientific terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any method or material similar or equivalent to the recorded content may also be applied to the present invention.

[0041] Example 1: Mining the biosynthetic gene cluster of aromatic polyketide antibiotics albofungins by analyzing the genome sequence of Streptomyces monomycini NRRL B-24309

[0042] By performing bioinformatics analysis on the genome sequence of Streptomyces monomycini NRRL B-24309 (GenBank accession number: GCA_000715845.1), the inventors located a putative albofungins biosynthetic gene cluster albo, which has a high degree of homology with the three albofungins biosynthetic gene clusters that have been discovered. Figure 1 The following is a comparison of putative albofungins biosynthetic gene clusters from different bacterial species. The coding genes are shown in Table 1, including minimal PKS coding gene cassettes, multiple post-modification genes, regulatory genes, and transporter coding genes. The nucleotide sequence of the albo biosynthetic gene cluster of aromatic polyketides can be directly obtained through the NCBI database, which is the 9893-69075 bases of the nucleotide sequence of NCBI Reference Sequence: NZ_KL571059.1.

[0043] Table 1

[0044]

[0045]

[0046]

[0047] Table 2

[0048]

[0049]

[0050] Example 2: Cloning and heterologous expression of albofungins biosynthetic gene cluster

[0051] (1) Extraction of genomic DNA (gDNA) from Streptomyces monomycini NRRL B-24309

[0052] The spore solution of S. monomycini NRRL B-24309 was inoculated into 50mL of MYG liquid medium (10g / L malt extract broth, 4g / L yeast extract, 4g / L glucose) at a ratio of 0.1%, and cultured in a shake flask at 28°C until the late exponential growth period. Subsequently, the bacteria were collected by centrifugation at 4000rpm for 10min. The bacteria were resuspended in 12mL of buffer (50mMTris-HCl, pH 8.0, 25mM EDTA). Next, 20mg lysozyme and 0.5mg RNase A were added, and the mixture was mixed thoroughly and incubated at 37°C for 2 hours. Then, 5-10mg proteinase K was added and incubated at 37°C for 1 hour. Next, 1.2mL 10% SDS was added and incubated at 50°C for 2 hours. After that, 4.8mL 5mol / L NaCl was added, mixed and placed at room temperature for 20 minutes. Finally, gDNA was recovered by phenol-chloroform extraction.

[0053] (2) Synthesis of guide RNA (gRNA) at both ends of the albo gene cluster and pBE45 and pBE48 backbone DNA (receivers).

[0054] The gRNA molecule was obtained by in vitro transcription using a T7 high-yield transcription kit (Thermo Scientific) from a dsDNA template of 60 bp formed by annealing two ssDNA oligonucleotides. The dsDNA template consisted of a T7 promoter sequence and a gRNA sequence. The primer sequences are shown in Table 2.

[0055] pBE45 and pBE48 receivers were obtained by amplification using pBE45 and pBE48 plasmids (https: / / www.addgene.org / 174654 / ) as templates and Phanta Max Super-Fidelity DNA Polymerase (Vazyme). The reaction system and PCR amplification procedures were operated according to the product manual. pBE45 and pBE48 receivers contain 39 bp homologous fragments at both ends of the gene cluster, respectively. The amplification primer sequences are shown in Table 2.

[0056] (3) FnCas12a-mediated targeted cleavage of gene clusters

[0057] The reaction system is shown in Table 3 below:

[0058] Table 3

[0059]

[0060] The above reaction system was mixed and incubated at 37°C for 2h, then incubated at 65°C for 30min, then 3μL 10mg / mL RNase A was added and mixed and incubated at 37°C for 30min, and finally 3μL 20mg / mL proteinase K was added and mixed and incubated at 50°C for 30min. The reaction solution was transferred to a Phase Lock Gel (TIANGEN) centrifuge tube, and the albo gene cluster obtained by FnCas12a digestion was extracted by phenol chloroform method.

[0061] (4) In vitro assembly and transformation of the albo gene cluster with pBE45 and pBE48 receivers

[0062] The reaction system is shown in Table 4 below:

[0063] Table 4

[0064]

[0065] The above reaction system was incubated at 65°C for 10 min without T4 DNA polymerase, cooled to room temperature, and then T4 enzyme was added, incubated at 25°C for 1 h, 75°C for 20 min, and 50°C for 30 min. Then 1 μL 1 mM NAD + , 0.4 μL 10 mM dNTPs, 3 U T4 DNA polymerase and 1 μL E. coli DNA ligase, incubate at 37 °C for 1 h, and incubate at 75 °C for 20 min. The reaction solution was added dropwise to the MF-Millipore TM Dialyze on filter membrane for 30 min.

[0066] 10 μL of the dialyzed reaction solution was added to 70 μL of the prepared E. coli pBE14 Cre competent cells, and transient electroporation was performed using a Gene Pulser XCell Electroporation system (Bio-Rad) instrument (1 mm cuvette, 1250 V, 100 Ω, 25 μF). Then, 1 mL of LB liquid culture medium containing 5 mM MgCl2 was added, and the cells were shaken at 37°C for 75 min. Finally, the cells were collected and evenly spread on LB solid culture medium (50 μg / mL apramycin, 0.2 mM IPTG, 40 mg / L X-Gal).

[0067] (5) Verification of positive clones

[0068] Pick several white single colonies for PCR identification, and the results are as follows Figure 3 As shown, the clone corresponding to the correct target band was transferred to 5 mL LB liquid culture medium, and the plasmid was extracted (Hipure BAC DNA MiniKit, Magen) at 37°C for 15 h. The plasmid was digested with restriction endonuclease SnaBⅠ. The results are shown in Figure 4 As shown, the bands after restriction digestion were all correct, indicating that the albo gene cluster was successfully cloned.

[0069] (6) Heterologous expression of recombinant plasmids

[0070] The recombinant plasmid was transferred into E. coli WM6026 (containing 40 μg / mL 2,6-diaminopimelic acid) as the donor bacteria, and the model Streptomyces S. albus J1074 was used as the recipient bacteria for conjugation transfer. The conjugates were grown on SFM solid medium (15 g / L mannitol, 15 g / L soybean powder, 2 g / L NaCl, 15 g / L CaCO3, 20 g / L agar, pH 7.0-7.4) for about 3 days and then taken out of the 4 mm 2 Spores of different sizes were added to 20 μL DMSO, shaken at 100°C, 2000 rpm for 20 min, centrifuged at 20000 g for 30 s, and 2 μL of supernatant was added to 25 μL system for Colony PCR identification. The correct conjugants were collected with 40% glycerol, inoculated into 50 mL MYM liquid medium (10 g / L malt extract broth, 4 g / L yeast extract, 4 g / L maltose monohydrate) at 1‰, and shaken at 28°C for 5 days to obtain the engineered bacteria S.albus J1074::albo. The fermentation broth was centrifuged, the supernatant was mixed with ethyl acetate at a ratio of 1:1 for extraction, the ethyl acetate phase was concentrated under reduced pressure, and the crude extract was dissolved in methanol. After high performance liquid chromatography (HPLC) analysis and comparison with the control group S.albus J1074 (without albo gene cluster), three new absorption peaks were found, namely the absorption peaks corresponding to compounds 1, 2 and 3.

[0071] Example 3: Preparation and structural identification of compounds albofungins, chrestoxanthones A and chrestoxanthones C.

[0072] (1) Compound separation and purification

[0073] The engineered bacteria S.albus J1074::albo in Example 2 was expanded for fermentation culture, the fermentation broth and mycelium of the fermentation culture were separated, the mycelium was extracted with acetone three times, the remaining water mixture after the acetone was recovered from the extract was extracted with ethyl acetate, and the ethyl acetate phase was concentrated under reduced pressure to obtain extract A; the fermentation broth was extracted with ethyl acetate at a volume ratio of 1:1 (v / v), and the ethyl acetate phase was concentrated under reduced pressure to obtain extract B; extract A and extract B were mixed, the mixed extract A and extract B were mixed with 100-200 mesh silica gel, dry-loaded on a column, and gradient elution was performed using n-hexane / ethyl acetate as an eluent (from 100:0 to 0:100, v / v), detected by TLC, and the same fractions were collected to obtain Fr.1-Fr.7 in turn. The fraction Fr.6 eluted with ethyl acetate was separated and purified by gel column chromatography (Sephadex-LH20, methanol) and semi-preparative high performance liquid chromatography (semi-HPLC) (chromatographic conditions: 0-15min, 95% water: 5% acetonitrile, 15-20min, 50% water: 50% acetonitrile, 20-21min, 20% water: 80% acetonitrile, 21-24min, 100% acetonitrile, 24-30min, 95% water: 5% acetonitrile, chromatographic column Agilent ZORBAXSB-C18, specification 4.6×250mm, flow rate 2.5mL / min, peak times of compounds 1, 2 and 3 were 15.9min, 15.6min and 14.8min respectively) to obtain compounds represented by Formula 1, Formula 2 and Formula 3. HPLC analysis is as follows Figure 2 As shown, the compounds shown in Formula 1, Formula 2 and Formula 3 are compounds albofungins, chrestoxanthones A and chrestoxanthones C, respectively. The structural formulas of the compounds shown in Formula 1, Formula 2 and Formula 3 are as follows:

[0074]

[0075] (2) Compound structure analysis

[0076] NMR results of compound 1: 1H NMR(600MHz,DMSO-d6)δ13.58(1H,s,3-OH),12.94(1H,s,6-OH),7.01(1H,s,H-22),6.62(1H,s,H-24 ),5.61(1H,d,J=5.9Hz,H-27),5.42(1H,d,J=5.9Hz,H-27'),4.96(1H,dd,J=13.1,4.6Hz,H-19),4.8 3(1H,m,H-10),4.43(1H,t,J=7.8Hz,H-13),3.56(3H,s,Me-28),3.23(1H,dd,J=13.9,4.7Hz,H-20), 2.76(1H,m,H-20'),2.45(3H,s,Me-26),2.06(2H,m,H2-12),1.82(1H,m,H-11),1.73(1H,m,H-11'). 13 C NMR(150MHz,DMSO-d6)δ182.1(C-8),165.1(C-14),163.3(C-1),156.8(C-3),149.5(C-6),142.7 (C-16),141.7(C-25),140.4(C-21),136.3(C-23),130.3(C-17),130.1(C-18),120.3(C-9),113. 8(C-22),112.8(C-4),111.6(C-5),109.8(C-7),109.2(C-2),105.2(C-24),90.6(C-27),74.7(C -13),72.1(C-19),58.8(C-10),57.8(C-28),35.9(C-20),27.9(C-11),22.8(C-12),18.9(C-26).

[0077] NMR results of compound 2: 1H NMR(600MHz,DMSO-d6)δ13.82(1H,s,3-OH),12.93(1H,s,6-OH),11.80(1H,s,NH),6.98(1H,s,H-22),6.42(1H ,s,H-24),5.61(1H,d,J=5.9Hz,H-27),5.42(1H,d,J=5.9Hz,H-27'),5.14(1H,s,10-OH),4.96(1H,dd,J=13.0 ,4.7Hz,H-19),4.83(1H,m,H-10),4.44(1H,t,J=5.9Hz,H-13),3.56(3H,s,Me-28),3.21(1H,dd,J=13.9,4.7H z,H-20),2.74(1H,m,H-20'),2.25(3H,s,Me-26),2.07(2H,m,H2-12),1.82(1H,m,H-11),1.73(1H,m,H-11'). 13 C NMR(150MHz,DMSO-d6)δ182.1(C-8),166.8(C-1),165.1(C-14),158.0(C-3),149.5(C-6),142.7 (C-16),140.9(C-25),139.0(C-23),138.9(C-21),130.3(C-17),130.1(C-18),120.3(C-9),113. 9(C-22),113.0(C-4),111.6(C-5),109.8(C-7),109.4(C-2),104.9(C-24),90.6(C-27),74.7(C -13),72.1(C-19),58.8(C-10),57.8(C-28),35.9(C-20),27.9(C-11),22.8(C-12),18.6(C-26).

[0078] NMR results of compound 3: 1H NMR(600MHz,DMSO-d6)δ13.80(1H,s,3-OH),13.21(1H,s,6-OH),11.71(1H,s,NH) ,6.92(1H,s,H-22),6.41(1H,s,H-24),5.91(1H,d,J=7.0Hz,13-OH),5.08(1H,s,1 0-OH),4.84(1H,m,H-10),4.62(1H,m,H-13),3.88(3H,s,Me-27),2.25(3H,s,Me-2 6),2.10(1H,m,H-12),1.97(1H,m,H-12'),1.82(1H,m,H-11),1.74(1H,m,H-11'). 13 CNMR(150MHz,DMSO-d6)δ182.1(C-8),166.8(C-1),165.1(C-14),157.7(C-3),149.5(C-6),14 2.7(C-16),140.9(C-25),138.9(C-21),138.5(C-23),135.3(C-17),130.3(C-18),120.3(C-9 ),112.6(C-22),112.1(C-4),111.6(C-5),109.8(C-7),109.4(C-2),104.9(C-24),65.6(C-13 ),61.4(C-27),59.0(C-10),29.9(C-19),28.6(C-11),26.5(C-12),26.4(C-20),18.5(C-26).

[0079] Example 4: Determination of antibacterial activity of compounds albofungin, chrestoxanthones A and chrestoxanthones C

[0080] The antibacterial activities of compounds albofungin, chrestoxanthones A and chrestoxanthones C were measured, and the results are shown in Table 5.

[0081] Table 5 Antibacterial activity test results of compounds albofungin, chrestoxanthones A and chrestoxanthones C

[0082]

[0083]

[0084] As shown in Table 5, compound albofungin has the strongest activity. Albofungin exhibited significant antibacterial activity against Bacillus subtilis ATCC 6633, Bacillus halodurans C-125, Micrococcus luteus ATCC 4698, Streptococcus mutans ATCC25175, and Saccharomyces cerevisiae BY4741 and YSG50, and the minimum inhibitory concentration (MIC) was less than 1 ng / mL. In addition, albofungin also has a certain inhibitory effect on the growth of microorganisms such as Streptomyces (S.albus J1074), Staphylococcus epidermidis (Staphylococcus epidermidis15X154), Enterobacter cloacae, Pseudomonas fluorescens Pf-5, Candida and Aspergillus, and its MIC value is in the range of 0.032μg / mL to 4μg / mL. (AMP (ampicillin) and Amphotericin B (amphotericin B) are positive controls). At the same time, chrestoxanthones A and chrestoxanthones C also showed significant antibacterial activity against Bacillus subtilis ATCC 6633, Bacillus halodurans C-125, Micrococcus luteus ATCC 4698, Streptococcus mutans ATCC 25175, Streptomyces (S.albus J1074), Staphylococcus epidermidis 15X154, Enterobacter cloacae and Saccharomyces cerevisiae BY4741 and YSG50.

[0085] Example 5: Determination of anti-tumor activity and GLP-1 secretion promoting activity of the compound albofungin

[0086] (1) Cytotoxicity test of compound 1 (albofungin) on mouse mononuclear macrophage leukemia cells RAW 264.7

[0087] RAW 264.7 cells were seeded in 96-well plates and cultured overnight. Compound 1 (final concentration 20 μM) was added, and cell control, medium blank control, and LNMMA control were set up. They were cultured for 24 hours. CCK8 reagent was added 1 hour before the end of the culture. The absorbance value was measured at 450 nm on an ELISA reader until the end of the culture. The results are shown in Figure 5 A As shown in the left figure.

[0088] (2) Effect of compound 1 on LPS-induced NO production in RAW 264.7 cells

[0089] RAW 264.7 cells were seeded in 96-well plates and cultured overnight. Lipopolysaccharide (LPS) and compound 1 (final concentration 20 μM) were added, and blank control wells without LPS and LPS-stimulated control wells without drugs were set up. After 24 hours of culture, the supernatant was collected and the NO content was detected using a NO detection kit. The results are shown in Figure 5 AAs shown in the right figure.

[0090] Depend on Figure 5 A shows that compound 1 (compound albofungin) has significant inhibitory activity against leukemia tumor cells.

[0091] (3) Test of the inhibitory activity of compound 1 on colorectal cancer cells HCT116 and HT29

[0092] HCT116 and HT29 cells were inoculated in 96-well plates and cultured overnight. Compound 1 (final concentration 20 μM) was added, and a cell control and a culture medium blank control were set up; culture was continued for 72 hours, and CCK8 reagent was added 1 to 4 hours before the end of culture. The absorbance value was measured at 450 nm on an ELISA reader until the end of culture. The results are shown in Figure 5 C. Figure 5 As shown in D.

[0093] Depend on Figure 5 C. Figure 5 D shows that compound 1 (compound albofungin) has significant inhibitory activity against colorectal cancer cells.

[0094] (4) GLP-1 secretion promoting activity test of compound 1

[0095] Mouse small intestinal endocrine cells STC-1 were inoculated in 96-well plates pre-coated with Matrix Gel and cultured overnight. The culture medium was aspirated and KRBH Buffer was added. After 1 hour, compound 1 (diluted with KRBH Buffer containing 55.5mM glucose or glucose-free, final concentration 20μM) was added. After 1 hour of compound treatment, the supernatant was collected and the content of GLP-1 was detected using the Active GLP-1 kit. The results are shown in Figure 5 B. Among them, Figure 5B The left figure shows the test results of dilution with KRBH Buffer containing 55.5mM glucose. Figure 5 B (right) shows the test results of dilution with KRBH Buffer without glucose.

[0096] Depend on Figure 5 B It can be seen that compound 1 (compound albofungin) has an activity of promoting the secretion of GLP-1.

[0097] Compound 1 was tested for its partial antitumor activity. Figure 5 As shown, compound 1 has a significant effect on inhibiting the survival of mouse mononuclear macrophage leukemia cells RAW 264.7, with a cell survival rate of only 1.28%. Compound 1 has a significant inhibitory activity on the secretion of NO by RAW264.7 cells, with a NO secretion inhibitory activity of 99.75% at a concentration of 20 μM, and a cell half-inhibitory concentration IC50 of 0.04634 μM; compound 1 has a significant inhibitory activity on the proliferation of colorectal cancer cell lines HCT116 and HT29, with inhibition rates of 98.18% and 99.21%, respectively, and IC50 has reached the nanomolar level (5.113nM and 6.68nM); in addition, compound 1 can significantly promote the secretion of GLP-1 by mouse small intestinal endocrine cells STC-1 under both sugar and sugar-free conditions.

[0098] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention, which shall all be included in the scope of protection of the present invention.

Claims

1. A biosynthetic gene cluster of aromatic polyketide antibiotics albofungins, characterized in that: The nucleotide sequence of the biosynthetic gene cluster of the aromatic polyketide antibiotic albofungins is NCBI Reference Sequence: Bases 9893-69075 of the nucleotide sequence of NZ_KL571059.

1.

2. The biosynthetic gene cluster of aromatic polyketide antibiotics albofungins according to claim 1, characterized in that: The biosynthetic gene cluster contains 61 coding genes.

3. Use of the biosynthetic gene cluster of the aromatic polyketide antibiotic albofungins according to claim 1 or 2 in the preparation of compounds represented by formula 1, formula 2, and formula 3, wherein the structural formulas of the compounds represented by formula 1, formula 2, and formula 3 are as follows:

4. A method for preparing the compounds represented by Formula 1, Formula 2 and Formula 3, characterized in that: The steps include: a. Cloning and heterologous expression of the biosynthetic gene cluster of the aromatic polyketide antibiotic albofungins according to claim 1 or 2 in vitro; b. fermenting the heterologously expressed recombinant strain in step a, separating the mycelium and the fermentation broth, extracting the mycelium to obtain extract A, and extracting the fermentation broth to obtain extract B; c. Mixing the extract A and the extract B to obtain a total extract, and separating and purifying the total extract to obtain the compounds represented by Formula 1, Formula 2, and Formula 3; The structural formulas of the compounds represented by Formula 1, Formula 2 and Formula 3 are as follows:

5. The method for preparing the compounds of formula 1, formula 2 and formula 3 according to claim 4, characterized in that: In the step a, the heterologous expression of the biosynthetic gene cluster is carried out in Streptomyces albus J1074.

6. The method for preparing the compounds of Formula 1, Formula 2 and Formula 3 according to claim 4, characterized in that: In the step b, the mycelium is extracted, including: extracting the mycelium with acetone, recovering the acetone from the extract, extracting with ethyl acetate, and concentrating the ethyl acetate phase under reduced pressure to obtain extract A; The fermentation liquid is extracted, comprising: extracting the fermentation liquid with ethyl acetate, and concentrating the ethyl acetate phase under reduced pressure to obtain extract B.

7. The method for preparing the compounds of Formula 1, Formula 2 and Formula 3 according to claim 4, characterized in that: In the step c, the total extract is separated and purified, including: mixing the total extract with silica gel, dry-loading the sample, gradient eluting with n-hexane / ethyl acetate as eluent, detecting with TLC, collecting the same fractions, and obtaining Fr.1-Fr.7 in sequence, and separating and purifying the fraction Fr.6 eluted with ethyl acetate by gel column chromatography and semi-preparative high performance liquid chromatography.

8. Use of a compound represented by Formula 1, Formula 2 or Formula 3 in the preparation of an antibacterial drug, wherein the structural formula of the compound represented by Formula 1, Formula 2 or Formula 3 is as follows: The bacteria include at least one of Bacillus subtilis, Bacillus halodurans, Micrococcus luteus, Streptococcus mutans, Saccharomyces cerevisiae, Streptomyces, Staphylococcus epidermidis, Enterobacter, Pseudomonas fluorescens, Candida and Aspergillus.

9. Use of a compound represented by Formula 1, Formula 2 or Formula 3 in the preparation of an anti-tumor drug, wherein the structural formula of the compound represented by Formula 1, Formula 2 or Formula 3 is as follows: The tumor includes at least one of a leukemia tumor and a colorectal cancer tumor.

10. Use of a compound represented by Formula 1, Formula 2 or Formula 3 in the preparation of a drug for promoting GLP-1 secretion, wherein the structural formula of the compound represented by Formula 1, Formula 2 or Formula 3 is as follows: